Prolactin Receptor Protein (PRLR) (AA 25-235) (hFc Tag)

Catalog No. ABIN7275467

Recombinant Prolactin Receptor protein expressed in HEK-293 Cells.

Quick Overview for Prolactin Receptor Protein (PRLR) (AA 25-235) (hFc Tag) (ABIN7275467)

Target: Prolactin Receptor (PRLR)

Protein Type: Recombinant

Biological Activity: Active

Origin: Dog

Source: HEK-293 Cells

Purity: > 95 % as determined by Bis-Tris PAGE,> 95 % as determined by HPLC

Product Details

Protein Characteristics: AA 25-235

Purification tag / Conjugate: This Prolactin Receptor protein is labelled with hFc Tag.

Purpose: Canine PRLR Protein

Sequence: Gln25-Thr235

Characteristics: Recombinant Canine PRLR Protein is expressed from HEK293 with hFc (IgG1) tag at the C-Terminus.It contains Gln25-Thr235.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1 EU per μg by the LAL method.

Biological Activity Comment: Canine PRLR on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.,The purity of Canine PRLR is greater than 95% as determined by SEC-HPLC.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1 mg/mL for 500 μg or 1 mg lyophilized powder. Do not mix by vortex or vigorous shaking.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3 months after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: Prolactin Receptor (PRLR)

Alternative Name: PRLR

Background: Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers.

Molecular Weight: 53.89 kDa. Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.

NCBI Accession: XM_038663941

Pathways: JAK-STAT Signaling, Response to Growth Hormone Stimulus